Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap

As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to curb the trend before the U.S. loses key biotechnology capabilities. During these discussions, it was only fitting that Pfizer struck an eye-popping development deal with Innovent on 12 cancer meds. And Astellas, facing a key patent cliff, is telling investors how it plans to adapt. Plus more.